Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR (“Research on Adverse Drug events And Reports”) program
2018 ◽
Vol 79
(4)
◽
pp. 777-778
◽
Keyword(s):
2018 ◽
Vol 79
(3)
◽
pp. AB168
Keyword(s):
2010 ◽
Vol 160
(3)
◽
pp. 386-393
◽
Keyword(s):
Keyword(s):
2019 ◽
Vol 13
(Supplement_1)
◽
pp. S082-S082
2020 ◽
Vol 83
(2)
◽
pp. 382-387
◽
Keyword(s):
Keyword(s):
2007 ◽
Vol 7
(4)
◽
pp. 409-416
◽
Keyword(s):